{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Ftargeting-dll3-for-ep-necs-rnBn0K9t","width":444,"version":"1.0","type":"rich","title":"Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/0052e8d7-042d-484b-b0c9-970d431e45d4/101246-ep-nec-tm-rfp-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/01a954e9-dfb1-42a0-981c-41bad5080929\" height=\"200\" width=\"100%\" title=\"Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes."}